论文部分内容阅读
蛛网膜下腔出血(SAH)所致脑血管痉挛(CVS)和脑梗塞是致死致残的主要原因。防治CVS是治疗SAH的关键问题。SAH后CVS的发生率约50％,发生时间多在1～14d。近年来对尼莫地平治疗CVS报道较多,但山莨菪碱(654—2)治疗SAH后的CVS报道甚少。现将我们应用654—2与尼莫地平治疗SAH后的CVS的疗效对比研究报道如下:
Subarachnoid hemorrhage (SAH) induced cerebral vasospasm (CVS) and cerebral infarction are the main cause of death caused by disability. Prevention and treatment of CVS is the key issue for the treatment of SAH. The incidence of CVS after SAH about 50%, occurred in more than 1 ~ 14d. In recent years, CVS treatment of nimodipine reported more, but anisodamine (654-2) CVS after treatment of SAH rarely reported. Now we use 654-2 and nimodipine treatment of CVS after SAH comparative study reported the following: